U.S. Industrials Stock News

NYSE:PATH
NYSE:PATHSoftware

What Could UiPath (PATH) Orchestration News Reveal About Scaling Agentic AI?

UiPath (NYSE:PATH) released a global report highlighting orchestration as a key factor in scaling agentic AI beyond pilots. The research draws on enterprise survey data that points to connecting data, systems, and employees as a main adoption challenge. Philippines based PLDT Inc. used UiPath orchestration to roll out agentic AI at scale, reporting large productivity gains and faster customer response. UiPath's new orchestration report and the PLDT deployment are only part of the broader...
NYSE:T
NYSE:TTelecom

Is AT&T (T) Undervalued As Fiber And 5G Optimism Lifts Its Outlook?

Board refresh puts governance in focus for AT&T AT&T (T) just expanded its board from 10 to 11 directors, bringing in Fazal F. Merchant, a veteran finance executive with extensive transaction and technology experience. Merchant joins both the Audit and the Corporate Development and Finance Committees. This places him close to oversight of AT&T’s balance sheet, capital allocation and potential deal activity at a time when investors are watching those areas closely. AT&T shares have picked up...
NasdaqGS:PTC
NasdaqGS:PTCSoftware

PTC (PTC) Could Be 25% Undervalued As AI Adoption Drives Its Growth Story

PTC (PTC) has drawn investor attention after recent trading left the stock down about 12% over the past month, even as the past 3 months show a gain of roughly 15%. Viewed over a longer stretch, PTC’s recent slide fits into a tougher year, with the year to date share price return down 23.12% and the 1 year total shareholder return declining 36.24%, even though the 90 day share price return is up 15.04%. Scan how PTC compares to other software names under pressure this year by reviewing our...
NasdaqGS:TLN
NasdaqGS:TLNRenewable Energy

Has Talen Energy (TLN) Fallen Far Enough To Look Cheap?

Talen Energy has delivered a very large gain over the past three years, yet the share price has recently pulled back and the valuation checks now point to a mixed picture rather than a clear bargain or clear overpricing. Over the past three years, Talen Energy is up very sharply, which puts the current weakness into the context of a powerful earlier recovery. Future valuation can depend on how reliably the business converts its asset base into cash flow. Any setback in execution or higher...
NasdaqGS:LRCX
NasdaqGS:LRCXSemiconductor

Is Lam Research (LRCX) Undervalued After Its Pullback and AI Memory Focus?

Lam Research (LRCX) is back in focus after Barometer Capital Management flagged the stock as a key positive contributor in Q2 2026, citing strong exposure to memory equipment tied to AI demand. Lam Research shares have cooled in recent weeks, with the 30-day share price return down 8.6% and the 90-day move down 18.7%. The stock still carries a strong year to date share price gain of 61.2% and a one year total shareholder return of 156.4%. Momentum has therefore eased near the US$298.22 level...
NYSE:CAT
NYSE:CATMachinery

What Is Caterpillar (CAT) Signaling With Its New Dozer And Record Power Sales?

Caterpillar (NYSE:CAT) introduced the Cat D11 XE electric-drive dozer, highlighting gains in fuel efficiency, productivity, and emissions performance. The firm reported record power and energy sales, tied to strong data center demand and changing preferences in generator technology. Management linked results to a shift toward hybrid and battery-integrated generator systems in the global power market. The Cat D11 XE launch and record power and energy performance sit within wider shifts our...
NasdaqGS:KLIC
NasdaqGS:KLICSemiconductor

Kulicke And Soffa Industries (KLIC) Could Be 19% Undervalued After AI Packaging Push

Kulicke and Soffa Industries (KLIC) just put its Thermo Compression Bonding and fluxless packaging technology in the spotlight as the semiconductor sector leans into Co Packaged Optics for AI focused networking and data center hardware. Recent trading has reflected that story. Kulicke and Soffa Industries has seen the share price climb 3.75% over the last day and 5.48% across the week, yet pull back 9.53% over 30 days and 23.91% over 90 days. A 78.05% year to date share price return and...
NYSE:DIS
NYSE:DISEntertainment

Walt Disney (DIS) Following InterDigital Claim Has An Undervalued Narrative Under Pressure

InterDigital’s latest damages claim against Walt Disney (DIS), seeking €101.7 million over streaming video patents after several European injunctions, has pushed legal risk around Disney’s direct to consumer platforms back into focus. Disney’s legal setback lands at a tricky moment for the stock, with the 90 day share price return of 6.5% and 30 day gain of 3.2% contrasting with a year to date share price decline of 4.7%. Legal headlines, new content like National Geographic’s upcoming AFRICA...
NasdaqGS:WTW
NasdaqGS:WTWInsurance

Why Everyone Is Watching Willis Towers Watson (WTW) Right Now

Willis Towers Watson (WTW) has put AI execution in sharper focus after announcing a partnership with Lyzr, aiming to help clients embed agentic AI workflows directly into everyday operations and workforce decisions. Recent trading shows a mixed picture for Willis Towers Watson. The share price is US$315.61 after a 7 day decline of 5.71% and a 30 day fall of 7.25%. However, the 90 day share price return of 20.17% and 3 year total shareholder return of 59.87% point to momentum that has built...
NasdaqGS:LAUR
NasdaqGS:LAURConsumer Services

Laureate Education (LAUR) Following Latin America Growth Narrative Is It A Buying Opportunity

Laureate Education (LAUR) most recently closed at $36.14, drawing fresh attention from investors reviewing education stocks after a period of mixed short term returns and a stronger performance over the past year. The recent 1-day share price gain of 1.02% comes after softer 7-day and 30-day share price returns. Laureate Education’s 1-year total shareholder return of 22.97% and very large 5-year total shareholder return of about 3.4x suggest longer term momentum has been much stronger than...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

STAAR Surgical (STAA) Says Implantable Lenses Are Taking Share From Laser Surgery

STAAR Surgical (NasdaqGM:STAA) released a global market report on 12 September 2026 on vision correction procedure trends. The study highlights a structural shift in multiple regions away from laser eye surgery toward implantable lens correction using phakic ICLs. STAAR Surgical reports that surgeons and patients show growing interest in reversible procedures that are presented as carrying safety advantages. This fresh data on a move from laser to implantable lens correction should not be...
NasdaqGM:IBEX
NasdaqGM:IBEXProfessional Services

IBEX (IBEX) Stock Rallies As Revenue Strength Meets Profit Friction

IBEX just jumped 6.8% to about $39.80, which indicates that traders reacted positively to the headline. The company reported record full year revenue of $644.1m and adjusted earnings per share of $3.52, while holding a net cash position of roughly $30.9m. In the short term, this reflects a relief pop after a stronger than usual quarter. For anyone with a longer time horizon measured in years rather than days, the combination of rising revenue and improving profitability is an important part...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

QUALCOMM (QCOM) Makes Its 6G And AI Push Harder To Ignore

QUALCOMM (QCOM) under CEO Cristiano Amon is intensifying investment in 6G research, AI data centers, robotics, and edge computing. The company is highlighting new use cases for 6G such as integrated sensing along with AI applications in smart infrastructure and national security. Management is framing this shift as a move beyond mobile devices toward broader wireless and AI-enabled markets. QUALCOMM's 6G and AI expansion push under Cristiano Amon comes alongside wider shifts our research has...
NasdaqGS:MU
NasdaqGS:MUSemiconductor

Micron Stock Is A Key Read On AI Memory Demand Right Now

Central banks are hinting at interest rate shifts while trade policy keeps markets on edge, and that mix can quickly reward or punish global cyclical growth stocks exposed to these crosswinds. Miss the right stories and you risk watching others catch the upside in real time. This article explains how this backdrop connects to three specific stocks from our Global Cyclical Growth Stocks screener and why their reactions to the news deserve a closer look. The three stocks highlighted below are...
NYSE:FTK
NYSE:FTKChemicals

Flotek Industries (FTK) Stock Looks Overvalued After A 7x Run

Flotek Industries has delivered a very large 3 year return, yet its current valuation checks lean expensive, so anyone looking at the stock today has to weigh strong recent gains against a weaker value score. Over the past 3 years, Flotek Industries has returned roughly 7x, which puts recent enthusiasm in sharp contrast with the cautious read from broader valuation metrics. Stronger expectations around international chemistry sales can support the current share price, while any...
NasdaqGS:ECHO
NasdaqGS:ECHOMedia

EchoStar (ECHO) Stock Looks Fully Valued With Cash Flow And Sales Rich

EchoStar has delivered a very large 3 year gain, yet both its intrinsic value estimate and market multiples currently point to a stock that trades at a premium to what the underlying cash flows might support. For anyone watching EchoStar today, price action and valuation checks are pulling in the same direction, toward a richer market tag. The share price return over the past 3 years is about 396%, which puts recent strength front and center for anyone assessing what is already priced...
NYSE:ZBH
NYSE:ZBHMedical Equipment

Zimmer Biomet (ZBH) Stock Looks Cheap Relative To Fair Value

Zimmer Biomet Holdings stock has had a difficult run over the past few years, yet the current valuation checks still lean toward the shares being cheap rather than expensive. The question for you is whether a weak long term share price record is masking an opportunity or simply reflecting the underlying business reality. Over the past 5 years, Zimmer Biomet Holdings has declined about 31.4%, which suggests investors have been cautious on the stock for a sustained period. Recent leadership...
NasdaqGS:FLWS
NasdaqGS:FLWSSpecialty Retail

1-800-FLOWERS.COM (FLWS) Stock Faces Shrinking Sales And Debt Pressure

1-800-FLOWERS.COM stock barely budged on the results, slipping less than 1% and leaving the share price near US$3 after a tough year where the chart has steadily ground lower. The market shrugged; the income statement did not. Quarterly revenue came in around US$293 million while the business posted another sizeable net loss, keeping the trailing twelve month earnings in the red. For short term traders, it looks like more of the same. Long term holders are staring at a different puzzle, with...
NYSE:TDG
NYSE:TDGAerospace & Defense

Is TransDigm Group (TDG) Fully Priced Or Still A Bargain?

TransDigm Group stock has pulled back in recent months, yet the current share price still sits well above where it traded five years ago. A Discounted Cash Flow (DCF) intrinsic value estimate points to a material gap against the market price. With broader valuation checks sending a mixed signal rather than a clear cheap or expensive label, investors are left weighing a rich long term share performance against what the cash flow math suggests today. Over the past 5 years, TransDigm Group has...
NYSE:NKE
NYSE:NKELuxury

Nike (NKE) Launches $NKE Stock Token On Solana

Nike (NYSE:NKE) launched a $NKE stock token on the Solana blockchain through Sunrise, opening onchain access to its equity. The tokenized format allows crypto-native investors to trade exposure to Nike shares through Solana-based decentralized finance platforms. Sunrise acts as the onchain venue for $NKE token activity, connecting traditional equity exposure with Solana wallets and trading tools. Nike's move to issue a $NKE stock token on Solana through Sunrise fits into a wider shift toward...
NYSE:BETA
NYSE:BETAAerospace & Defense

BETA Technologies (BETA) Joins Electric Skyways Push, Is It A Bargain?

BETA Technologies (BETA) is back in focus after helping launch America’s Consortium for Electric Skyways, a Texas-focused eVTOL charging effort tied to the White House’s integration pilot program, along with a fresh appearance at Jefferies’ Global Industrials Conference. Investors have reacted quickly to the ACES announcement and conference exposure, with BETA Technologies’ share price rising 6.44% on a 1 day basis to US$21.17, even though the 30 day share price return is down 10.98% and the...
NasdaqGM:LOVE
NasdaqGM:LOVEConsumer Durables

Lovesac (LOVE) Stock Profit Relies On Tariff Refund As Demand Softens

Lovesac stock eased 2.5% to US$13.91 into Friday’s close, which looks tame given how emotionally charged furniture earnings can get. The headline is simple. The company printed a profitable Q2 on paper, with US$0.51 in earnings per share and US$7.4m of net income, but that picture leans heavily on a one time US$21m tariff refund. When that refund is excluded, the quarter tilts back toward an adjusted EBITDA loss. Traders appear conflicted. The mild price dip signals fatigue, while the...
NasdaqGS:SKWD
NasdaqGS:SKWDInsurance

What Does Skyward Specialty Insurance Group (SKWD) Apollo Integration Mean For Earnings?

Skyward Specialty Insurance Group (NasdaqGS:SKWD) reports that the integration of Apollo is creating a new fee-based earnings stream. Management describes the Apollo unit as materially additive to overall earnings, shifting part of the business toward fee-driven revenue. The integration is expected to change Skyward Specialty Insurance Group's revenue mix, with a larger share tied to recurring fee income. This new Apollo fee-based earnings stream is an important shift to weigh against the...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

IDEAYA Biosciences (IDYA) Doses First Patient In Phase 3 Uveal Melanoma Trial

IDEAYA Biosciences (NasdaqGS: IDYA) and Servier have dosed the first patient in the OptimUM-11 global Phase 3 trial. OptimUM-11 is evaluating darovasertib plus crizotinib as adjuvant therapy for primary uveal melanoma patients at high risk of metastasis. The study is described as the first global registrational trial of this drug combination in the adjuvant setting for primary uveal melanoma. The launch of the OptimUM-11 Phase 3 darovasertib and crizotinib adjuvant trial is a key development...